6.6.1. Calcitonin and parathyroid hormone

Restrictions:
Restricted to specialist use for postmenopausal people with osteoporosis at very high risk of fracture, assessed using a validated fracture risk assessment tool.
Prescribing Notes:
To be used 3rd line in patients where romosuzumab and teriparatide are considered unsuitable, ineffective or not tolerated

Restrictions:
Restricted to specialist use for the treatment of established severe osteoporosis in post-menopausal women for whom parathyroid hormone (PTH 1-84) is not tolerated or appropriate. The treatment of osteoporosis associated with glucocorticoid therapy and the treatment of osteoporosis in men at increased risk of fracture is not recommended by SMC and is non-Formulary.
Prescribing Notes:
The preferred brand is Movymia®.